HK Stock MarketDetailed Quotes

01177 SINO BIOPHARM

Watchlist
  • 3.370
  • -0.030-0.88%
Not Open Nov 12 16:08 CST
63.33BMarket Cap14.10P/E (TTM)

About SINO BIOPHARM Company

China Biopharmaceutical Co., Ltd. (the “Company” or “China Biopharmaceutical”) and its subsidiaries (the “Group”) is a leading innovative research and development-driven pharmaceutical group in China. Its business covers the entire industry chain of pharmaceutical R&D platforms, intelligent production and a strong sales system. The products include a variety of biopharmaceuticals and chemicals, and are in an advantageous position in the four major treatment fields of cancer, liver disease, respiratory system, and surgery/analgesia. The Company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a constituent stock of the MSCI Global Standard Index in 2013; selected as a constituent stock of the Hang Seng China Enterprise Index in 2018; selected as a constituent stock of the Hang Seng China Enterprise Index in 2019; as a constituent stock of the Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect Biotech 50 Index and Hang Seng China (Hong Kong Listed) 25 Index in 2020. China Biopharmaceuticals has been ranked in the “Top 50 Global Pharmaceutical Companies” published by the authoritative American magazine “Pharmaceutical Manager” for 5 consecutive years, and has been named “Top 50 Best Companies in Asia Pacific” by “Forbes” (Asia) for 3 consecutive years. Chinese biopharmaceutical companies are distributed in Beijing, Shanghai, Nanjing, Lianyungang, etc., and have multiple pharmaceutical production bases. Since its establishment, the company has continued to achieve outstanding achievements and steady development. The core member companies, Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Beijing Tide Pharmaceutical Co., Ltd. have all been on the list of China's top 100 pharmaceutical industry enterprises for many years. The company takes replication as the foundation, comprehensively transforms to innovation, drives growth, and its share of revenue is increasing year by year; the internal research pipeline drives innovation and transformation, continuously improving the technology platform; and actively promotes the internationalization process under the leadership of a top scientific team to seize the international frontier circuit. China Biopharmaceuticals will adhere to the mission of “health technology to warm more lives”, focus on innovation, serve patients, and strive to become the world's leading pharmaceutical company. We hope to share the development achievements of the medical and health industry with people of insight, and make every effort to cooperate and win the future together! The Group's main subsidiaries include Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”), Beijing Tide Pharmaceutical Co., Ltd. (“Beijing Tide”), Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. (“Nanjing Zhengda Tianqing”), Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. (“Jiangsu Zhengda Qingjiang”), and InvoX Pharma Limited (“InvoX”). Nanjing Zhengda Tianqing, Jiangsu Zhengda Qingjiang, and Jiangsu Zhengda Fenghai were recognized by the Jiangsu Provincial Science and Technology Department as “Jiangsu Anti-tumor and Cardiovascular Phytochemical Pharmaceutical Engineering Technology Research Center”, “Orthopedic Pharmaceutical Formulation Engineering Technology Research Center”, and “Parenteral Nutrition Engineering Technology Research Center” by the Jiangsu Provincial Department of Science and Technology, respectively. The Chia Tai Tianqing R&D Center is a “postdoctoral research workstation” granted by the Chinese Ministry of Social Affairs. It is the only “novel liver disease drug engineering technology research center” in China. Beijing Tide once again obtained GMP certification from Japan's Ministry of Health, Labor, and Welfare for foreign pharmaceutical companies in December 2012. Japanese pharmaceutical companies can entrust Beijing Tide to manufacture and export sterile pharmaceutical preparations under development and already on the market in Japan to Japan.

Company Profile

Symbol01177
Company NameSINO BIOPHARM
ISINKYG8167W1380
Listing DateDec 8, 2003
FoundedFeb 2, 2000
Registered AddressCayman Islands
Chairmanqirun xie
Secretarykainian chen
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeCodan Trust Company (Cayman) Limited Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
Head Office and Principal Place of BusinessRoom 09, 41st floor, Convention & Exhibition Centre Office Tower, 1 Harbour Road, Wanchai, Hong Kong
Fiscal Year Ends12-31
Employees24437
MarketHong Kong motherboard
Phone(+852) 2802 9886
Fax(+852) 2880 0847
Emailinfo@sino-biopharm.com
Business China Biopharmaceutical Co., Ltd. is an investment holding company mainly engaged in the pharmaceutical business. The company operates through three divisions. The Traditional Chinese Medicine and Western Medicine Division is mainly engaged in the production, sale and distribution of modern Chinese medicine formulation products and Western medicine products. The Investment Division is mainly engaged in long-term and short-term investments. Other divisions are mainly engaged in related medical and hospital business.

Company Executives

  • Name
  • Position
  • Salary
  • qirun xie
  • Presidencies, Executive Director, Chairman of the Executive Board Committee, Chairman of the Nomination Committee
  • 49.69M
  • bing xie
  • Executive Director, Senior Vice Chairman of the Board, Nomination Committee Members, Member of the Executive Board Committee, Authorized Representative
  • 49.53M
  • xiangling zheng
  • Vice-chairman, Executive Director, Member of the Executive Board Committee
  • 43.13M
  • chengrun xie
  • Executive Director, Chief Executive, Member of the Executive Board Committee
  • 49.69M
  • xin xie
  • VP, Executive Director, Member of the Executive Board Committee
  • 6.41M
  • zhoushan tian
  • Executive Director
  • 1.91M
  • zhengfei lu
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
  • 376.00K
  • dakui li
  • Independent Non-Executive Director, Audit Committee Members
  • 376.00K
  • hong lu
  • Independent Non-Executive Director, Audit Committee Members, Remuneration Committee Members, Nomination Committee Members
  • 342.00K
  • lufu zhang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
  • 376.00K
  • guodong li
  • Independent Non-Executive Director, Nomination Committee Members, Audit Committee Members
  • 376.00K
  • penggen chen
  • Chief Strategy Officer
  • --
  • chunling li
  • Chief Financial Officer
  • --
  • Mr. Ben Toogood
  • CEO of InvoX Pharma Limited and Head of the Global Business of Biopharmaceuticals in China
  • --
  • song jin
  • VP
  • --
  • kainian chen
  • Authorized Representative, Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data